Athersys (ATHX) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends ATHX vs. KTTA, SHPH, ZVSA, DWTX, INM, MTNB, QLGN, ARAV, QNRX, and DRMAShould you be buying Athersys stock or one of its competitors? The main competitors of Athersys include Pasithea Therapeutics (KTTA), Shuttle Pharmaceuticals (SHPH), ZyVersa Therapeutics (ZVSA), Dogwood Therapeutics (DWTX), InMed Pharmaceuticals (INM), Matinas Biopharma (MTNB), Qualigen Therapeutics (QLGN), Aravive (ARAV), Quoin Pharmaceuticals (QNRX), and Dermata Therapeutics (DRMA). These companies are all part of the "pharmaceutical preparations" industry. Athersys vs. Pasithea Therapeutics Shuttle Pharmaceuticals ZyVersa Therapeutics Dogwood Therapeutics InMed Pharmaceuticals Matinas Biopharma Qualigen Therapeutics Aravive Quoin Pharmaceuticals Dermata Therapeutics Athersys (NASDAQ:ATHX) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability. Which has more volatility & risk, ATHX or KTTA? Athersys has a beta of -0.9, meaning that its share price is 190% less volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Does the media refer more to ATHX or KTTA? In the previous week, Athersys and Athersys both had 1 articles in the media. Pasithea Therapeutics' average media sentiment score of 0.49 beat Athersys' score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athersys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pasithea Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings and valuation, ATHX or KTTA? Pasithea Therapeutics has lower revenue, but higher earnings than Athersys. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAthersys$146K0.00-$72.53M-$2.03N/APasithea TherapeuticsN/AN/A-$15.96MN/AN/A Is ATHX or KTTA more profitable? Athersys' return on equity of 0.00% beat Pasithea Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AthersysN/A N/A -223.03% Pasithea Therapeutics N/A -81.57%-74.31% Do insiders & institutionals have more ownership in ATHX or KTTA? 19.4% of Athersys shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 0.0% of Athersys shares are owned by insiders. Comparatively, 16.3% of Pasithea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community favor ATHX or KTTA? Athersys received 363 more outperform votes than Pasithea Therapeutics when rated by MarketBeat users. Likewise, 57.48% of users gave Athersys an outperform vote while only 40.00% of users gave Pasithea Therapeutics an outperform vote. CompanyUnderperformOutperformAthersysOutperform Votes36557.48% Underperform Votes27042.52% Pasithea TherapeuticsOutperform Votes240.00% Underperform Votes360.00% SummaryPasithea Therapeutics beats Athersys on 6 of the 10 factors compared between the two stocks. Get Athersys News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHX vs. The Competition Export to ExcelMetricAthersysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$833,000.00$6.52B$5.34B$9.11BDividend YieldN/A2.96%5.37%4.00%P/E Ratio-0.014.4457.4913.22Price / SalesN/A310.281,275.6876.05Price / CashN/A22.6336.6032.90Price / BookN/A4.964.874.58Net Income-$72.53M$154.90M$118.05M$224.84M Athersys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHXAthersysN/AN/AN/AN/A$833,000.00$146,000.00-0.0124KTTAPasithea Therapeutics0.784 of 5 stars$2.62+2.3%N/A-65.2%$3.32M$20,000.000.003SHPHShuttle Pharmaceuticals0.6628 of 5 stars$0.90+3.4%N/AN/A$3.30MN/A-0.225Positive NewsZVSAZyVersa Therapeutics3.1908 of 5 stars$1.33-9.5%$120.00+8,922.6%-74.2%$3.11MN/A0.002Positive NewsGap DownDWTXDogwood TherapeuticsN/A$2.32-1.7%N/AN/A$3.09MN/A-0.355Positive NewsINMInMed Pharmaceuticals1.0061 of 5 stars$4.22-2.1%N/A-31.0%$3.06M$4.96M-0.3010Positive NewsMTNBMatinas BiopharmaN/A$0.60-3.6%N/AN/A$3.04M$1.10M-0.1230QLGNQualigen TherapeuticsN/A$4.10-4.2%N/A-83.8%$3.02M$4.98M0.0050Positive NewsARAVAraviveN/A$0.04flatN/AN/A$2.95M$6.99M-0.0420QNRXQuoin Pharmaceuticals3.3496 of 5 stars$0.57-8.0%$4.00+599.8%-84.8%$2.89MN/A-0.144DRMADermata Therapeutics1.7647 of 5 stars$1.38+15.0%$6.00+334.8%-77.9%$2.82MN/A-0.088Short Interest ↑Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Pasithea Therapeutics Competitors Shuttle Pharmaceuticals Competitors ZyVersa Therapeutics Competitors Dogwood Therapeutics Competitors InMed Pharmaceuticals Competitors Matinas Biopharma Competitors Qualigen Therapeutics Competitors Aravive Competitors Quoin Pharmaceuticals Competitors Dermata Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATHX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athersys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athersys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
